PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1067.86%
EBIT growth above 1.5x AVXL's 25.08%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
39.05%
Operating income growth above 1.5x AVXL's 25.08%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
24.67%
Net income growth above 1.5x AVXL's 9.98%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
25.26%
EPS growth above 1.5x AVXL's 12.00%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
25.26%
Diluted EPS growth above 1.5x AVXL's 16.00%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.67%
Negative OCF growth while AVXL is at 23.50%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-25.67%
Negative FCF growth while AVXL is at 23.50%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.29%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-10.29%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-46.03%
Negative 3Y OCF/share CAGR while AVXL stands at 7.98%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
68.39%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
68.39%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
65.23%
3Y net income/share CAGR 1.25-1.5x AVXL's 47.69%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
-358.21%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-358.21%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-14.02%
Negative 3Y equity/share growth while AVXL is at 62.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.24%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
8.21%
Debt growth far above AVXL's 4.83%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-39.30%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.